ADAPTIVE BIOTECHNOLOGIES CORPORATION Weighted Average Number of Shares Outstanding, Basic and Diluted
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 141.70 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 141.70M shares, a 1.96% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 141.24M shares, a 3.10% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 140.83M shares, a 4.81% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 140.36M shares, a 10.19% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 140.35M shares, a 6.96% increase from fiscal 2020.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 131.22M shares, a 89.71% increase from fiscal 2019.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 69.17M shares, a 447.64% increase from fiscal 2018.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 12.63M shares, a 3.55% increase from fiscal 2017.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 141.70M shares 10-Q · filed 2022-05-04 | 141.47M shares derived: average of 2 quarters · filed 2022-05-04 | 141.26M shares derived: average of 3 quarters · filed 2022-05-04 | 141.03M shares derived: average of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | 141.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | 141.04M shares derived: average of 2 quarters · filed 2022-02-15 | 140.81M shares derived: average of 3 quarters · filed 2022-02-15 | 140.35M shares 10-K · filed 2022-02-15 |
| 2021-09-30 | 140.83M shares 10-Q · filed 2021-11-03 | 140.60M shares derived: average of 2 quarters · filed 2021-11-03 | 140.06M shares 10-Q · filed 2021-11-03 | 139.29M shares derived: average of 4 quarters · filed 2022-05-04 |
| 2021-06-30 | 140.36M shares 10-Q · filed 2021-08-04 | 139.67M shares 10-Q · filed 2021-08-04 | 138.77M shares derived: average of 3 quarters · filed 2022-05-04 | 137.67M shares derived: average of 4 quarters · filed 2022-05-04 |
| 2021-03-31 | 138.97M shares 10-Q · filed 2022-05-04 | 137.98M shares derived: average of 2 quarters · filed 2022-05-04 | 136.78M shares derived: average of 3 quarters · filed 2022-05-04 | 134.43M shares derived: average of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | 137.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | 135.68M shares derived: average of 2 quarters · filed 2022-02-15 | 132.92M shares derived: average of 3 quarters · filed 2022-02-15 | 131.22M shares 10-K · filed 2022-02-15 |
| 2020-09-30 | 134.37M shares 10-Q · filed 2021-11-03 | 130.88M shares derived: average of 2 quarters · filed 2021-11-03 | 129.29M shares 10-Q · filed 2021-11-03 | 128.20M shares derived: average of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | 127.38M shares 10-Q · filed 2021-08-04 | 126.72M shares 10-Q · filed 2021-08-04 | 126.15M shares derived: average of 3 quarters · filed 2022-02-15 | 125.68M shares derived: average of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | 126.06M shares 10-Q · filed 2021-05-05 | 125.53M shares derived: average of 2 quarters · filed 2022-02-15 | 125.12M shares derived: average of 3 quarters · filed 2022-02-15 | 97.16M shares derived: average of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | 125.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | 124.64M shares derived: average of 2 quarters · filed 2022-02-15 | 87.52M shares derived: average of 3 quarters · filed 2022-02-15 | 69.17M shares 10-K · filed 2022-02-15 |
| 2019-09-30 | 124.29M shares 10-Q · filed 2020-11-10 | 68.78M shares derived: average of 2 quarters · filed 2020-11-10 | 50.55M shares 10-Q · filed 2020-11-10 | 40.92M shares derived: average of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | 13.28M shares 10-Q · filed 2020-08-10 | 13.07M shares 10-Q · filed 2020-08-10 | 13.13M shares derived: average of 3 quarters · filed 2021-02-24 | 13.00M shares derived: average of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | 12.89M shares 10-Q · filed 2020-05-12 | 13.06M shares derived: average of 2 quarters · filed 2021-02-24 | 12.91M shares derived: average of 3 quarters · filed 2021-02-24 | 12.78M shares derived: average of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | 13.23M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | 12.92M shares derived: average of 2 quarters · filed 2021-02-24 | 12.74M shares derived: average of 3 quarters · filed 2021-02-24 | 12.63M shares 10-K · filed 2021-02-24 |
| 2018-09-30 | 12.62M shares 10-Q · filed 2019-11-12 | 12.50M shares derived: average of 2 quarters · filed 2019-11-12 | 12.43M shares 10-Q · filed 2019-11-12 | |
| 2018-06-30 | 12.39M shares 10-Q · filed 2019-08-13 | 12.33M shares 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | 12.20M shares 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |